A rare G2061 insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype

Pharmacogenetics

Volumn 9, Issue 3, 1999, Pages 393-396

  Marez Allorge, D ^a   Ellis, S W ^b   Lo Guidice, J M ^a   Tucker, G T ^b   Broly, F ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

CYP2D6; Genetic polymorphism; Pharmacogenetic; Poor metabolizer

Indexed keywords

CYTOCHROME P450; METOPROLOL; CYTOCHROME P450 2D6; PRIMER DNA;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; GENE AMPLIFICATION; GENE INACTIVATION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; OPEN READING FRAME; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; BIOTRANSFORMATION; GENETICS; NUCLEOTIDE SEQUENCE; SINGLE STRAND CONFORMATION POLYMORPHISM;

BASE SEQUENCE; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; DNA PRIMERS; HUMANS; OPEN READING FRAMES; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0033141361     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199906000-00015     Document Type: Article

References (14)

1. Broly F, Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Meyer UA. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995; 5:373-384.
2. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of Tamoxifen bu human liver microsomes. Biochem Pharmacol 1997; 53:171-178.
3. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 1994; 102:55-61.
4. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
5. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MMS, Simula AP, et al. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 1995; 270:29055-29058.
6. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336:529-532.
7. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez F. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 1989; 45:889-904.
8. Legrand-Andréoletti M, Stücker I, Marez D, Galais P, Cosme J, Sabbagh N, et al. Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians. Pharmacogenetics 1998:8: 7-14.
9. Linder MW, Prough RA, Valdes R Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997; 43:254-266.
10. Marez D, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, Lafitte J-J, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
11. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37:269-296.
12. 226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. Pharmacogenetics 1996; 6:269-272.
13. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339:1375-1377.
14. Stüven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 1996: 6: 417-421.